Cerevasc has announced that data from clinical studies examining the use of its eShunt system to treat elderly patients with normal-pressure hydrocephalus, and patients with communicating hydrocephalus following treatment for a ruptured cerebral aneurysm, were recently presented at the Congress of Neurological Surgeons (CNS) annual meeting (9–13 September, Washington DC, USA).
Adel Malek, Cerevasc chief medical officer and chief of Neurovascular Surgery at Tufts Medical Center (Boston, USA), delivered the following presentations at CNS 2023:
- ‘Development of a percutaneous endovascular biomimetic shunt (eShunt) for treatment of communicating hydrocephalus’
- ‘Use of the eShunt implant in treatment of aneurysmal subarachnoid haemorrhage communicating hydrocephalus’
- ‘Minimally invasive treatment of idiopathic normal-pressure hydrocephalus using the endovascular eShunt implant’
“We are now seeing the impact of our eShunt system in dozens of patients treated and we are thrilled by the results, and grateful for the opportunity to share them with the physician community,” Dan Levangie, Cerevasc president and CEO, stated. “The eShunt system provides the opportunity to treat both complicated conditions with a minimally invasive alternative to the current invasive standard of care. The data presented at CNS bolster our confidence in the potential of the eShunt system as we transition to broader use in a pivotal clinical trial in early 2024.”
This news follows other recent updates from Cerevasc, including the company’s announcement of US Food and Drug Administration (FDA)-approved expansion for its normal-pressure hydrocephalus study to include additional participants and clinical sites, as well as allowing the use of the second generation (Gen2) of the eShunt system in the trial.